JPRN-UMIN000010780
Completed
未知
Effects of teneligliptin on glycemic control and bone metabolic markers in diabetic patients undergoing hemodialysis - Effects of teneligliptin on glucose and bone metabolism in diabetic patients undergoing hemodialysis
Diamond study group0 sites10 target enrollmentMay 22, 2013
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- diabetic patients undergoing hemodialysis
- Sponsor
- Diamond study group
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients with severe liver dysfunction (AST more than 100 or ALT more than 100 IU/L) Patients with malignancy under medical treatmennt Patients with untreated diabetic retinopathy Patients terated with insulin injection Patients disqualified by doctor for any reason
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
The efficacy of teneligliptin in diabetic patients on hemodialysisType2 diabetic patients on hemodialysisJPRN-UMIN000010999Kawashima Hospital30
Completed
Not Applicable
Efficacy of linagliptin on glycemic control in diabetic patients on hemodialysis [Diamond study-1]Diabetic patients on hemodialysisJPRN-UMIN000007635Diamond study group80
Completed
Not Applicable
Effects of one of antidiabetic agents, teneligliptin, on the vascular endothelium function of ACS patients with diabetesAcute Coronary Syndrome (ACS) and diabetesJPRN-UMIN000018936Saitama Medical Center, Jichi Medical University50
Completed
Phase 4
Efficacy of Sitagliptin on glycaemic control in drug naïve patients with type 2 diabetes (STRICT-2)Type 2 Diabetes MellitusJPRN-UMIN000005460STRICT study Group300
Not yet recruiting
Not Applicable
Study of antidiabetic drugs on markers of inflammation in type 2 diabetes mellitus patients.CTRI/2018/03/012603MALEHA BUT